Durable Marked Response of Unresectable Esophageal Squamous Cell Carcinoma After Radiotherapy Alone Followed by Combination Immunotherapy.

Two randomized Phase II trials in non–small cell lung cancer [ 18 , 19 ] demonstrated that RT administered before or concurrently with anti–PD‐1 antibody prolonged PFS and showed a trend toward improved OS compared with ICI alone, with pooled analyses reporting a hazard ratio of 0.67 for both PFS and OS [ 20 ].

also in 53,322 other papers